October 15, 1996Circulation
The Asp 9 Asn Mutation in the Lipoprotein Lipase Gene Is Associated With Increased Progression of Coronary Atherosclerosis
Why the study?
Does the Asp9 Asn mutation in the LPL gene affect the progression of coronary atherosclerosis and the response to pravastatin in patients with coronary artery disease?
Population
819 patients with coronary atherosclerosis enrolled in the REGRESS trial
Comparison
Pravastatin therapy vs Placebo
Design
Cohort
Authors
Discussion
Loading...
Member takes
Implication
Should not yet guide LPL genotyping or therapy in CAD; leaves open mutation-statin interactions in randomized cohorts.
Structured PICO
Does the Asp9 Asn mutation in the LPL gene affect the progression of coronary atherosclerosis and the response to pravastatin in patients with coronary artery disease?
P
Population
819 patients with coronary atherosclerosis enrolled in the REGRESS trial
I
Intervention
Pravastatin therapy (analyzed by Asp9 Asn mutation carrier status)
C
Comparator
Placebo (analyzed by Asp9 Asn mutation carrier status)
O
Outcome
Progression of coronary atherosclerosis (change in minimum obstruction diameter and percentage diameter stenosis)surrogate
Heterozygosity for the Asp9 Asn mutation in the LPL gene is associated with increased progression of coronary atherosclerosis and higher risk of clinical events, though these patients still benefit from pravastatin therapy.
Cite This Study
Jukema et al. (1996) studied this question.